A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication of<i> Helicobacter</i><i> pylori:</i> A Non-Inferiority Clinical Trial

作者全名："Li, Juan; Lv, Lin; Zhu, Yongjun; Zhou, Zhihang; He, Song"

作者地址："[Li, Juan; Lv, Lin; Zhu, Yongjun; Zhou, Zhihang; He, Song] Chongqing Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Chongqing, Peoples R China; [Zhou, Zhihang; He, Song] Chongqing Med Univ, Affiliated Hosp 2, Dept Gastroenterol, 288 Tianwen Rd, Chongqing 400016, Peoples R China"

通信作者："Zhou, ZH; He, S (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Gastroenterol, 288 Tianwen Rd, Chongqing 400016, Peoples R China."

来源：INFECTION AND DRUG RESISTANCE

ESI学科分类：IMMUNOLOGY

WOS号：WOS:001058050500001

JCR分区：Q2

影响因子：2.9

年份：2023

卷号：16

期号：　

开始页：5637

结束页：5645

文献类型：Article

关键词：vonoprazan; amoxicillin; Helicobacter pylori; Jinghua Weikang capsule

摘要："Purpose: The emergence of resistant strains has greatly reduced the eradication rate of H. pylori (HP) in conventional bismuth containing quadruple therapy. Meanwhile, the new 7-day dual therapy with vonoprazan (VPZ) and amoxicillin (AMO) failed to achieve the expected therapeutic effect in China.Patients and Methods: A total of 256 untreated HP-infected patients are included in this non-inferiority clinical trial. The patients were randomly divided into three groups: 14-day dual therapy group (VPZ 20mg b.i.d + AMO 750mg t.i.d for 14 days, VA14), 14-day modified triple therapy group (VA14 + Jinghua Weikang Capsule 160mg t.i.d, VAC), and conventional bismuth-containing quadruple therapy group for 14 days (BCQ). Eradication rates, drug-related adverse events (AEs), patient compliance, and drug costs were compared among the three groups.Results: The eradication rates in the BCQ, VA14, and VAC were 78.67, 77.33%, and 86.49% by intention-to-treat analysis, respectively, and 96.72%, 90.63%, and 92.75% by pre-protocol or modified intention-to-treat analysis, respectively. VA14 therapy indicated a non-inferiority eradication rate and advanced safety and economics to BCQ therapy. JWC further improved the eradication rate and reduced the incidence of AEs.Conclusion: A modified 14-day dual therapy with VPZ and AMO provides satisfied efficacy as the first-line treatment for HP infection in China."

基金机构：　

基金资助正文：